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Cancer treatment is being revolutionized by the emergence of immunotherapies such
as immune checkpoint inhibitors and therapeutic cancer vaccines. Prostate cancer is
amenable to such therapeutic approaches.The improved understanding of the relationship
between the immune system and tumors has allowed therapeutic targeting of immune
checkpoints and tumor associated antigens to be developed. Furthermore, interventions
used in prostate cancer are capable of impacting the immune system. As demonstrated
by preclinical data and emerging clinical data, radiation therapy, anti-androgen therapy, and
chemotherapy can be used with immunotherapies to obtain synergistic results. Current
and future clinical trials will further investigate these principles as immunotherapeutics are
combined with each other and standard therapies for optimal clinical utility.
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INTRODUCTION
Prostate cancer is the most common malignancy in men diag-
nosed in the United States and is second in cancer related death
only surpassed by lung cancer, with 29,480 projected deaths in
2014 (1). Although recent years have seen great advances in treat-
ments for prostate cancer, including second-line chemotherapy,
anti-androgen therapies, and radiopharmaceuticals, none of these
therapies are curative (2). Nonetheless, there is great potential
for these and existing therapies to be used synergistically with
immunotherapies already in clinical practice or in late stages of
clinical trials. Furthermore, given the lack of significant toxicity
seen with therapeutic cancer vaccines and the lack of over-lapping
toxicity seen with immune checkpoint inhibitors, it appears pos-
sible that immune-based combinations have the potential for
improving clinical outcomes without causing patients significant
additional side effects. This is very important in a disease such as
prostate cancer where symptoms from the disease are generally
not present until the late stages (3).
Innate and adaptive immune responses have been studied as a
means of prevention and control of tumors (4, 5). The dynamic
process of immune activation against cancer can begin with anti-
gen presentation via dendritic cells (DCs) and other antigen pre-
senting cells (APCs) and recognition of those antigens by T cells via
the T cell receptor (TCR) (6–8). A subsequent maturation signal
[including toll like receptors (TLRs) or endogenous factors such as
high mobility group (HMG) proteins or adenosine tri-phosphate
(ATP) from the dying cells] is required from APCs to induce ade-
quate activation of T cells (6). Peptide antigen bound to the major
histocompatibility complex (MHC)-derived molecule is presented
to the TCR. This recognition and interaction is the central event
that leads to effector cellular immunity (7). In addition, the inter-
action and activation of the B7 family of co-receptors is crucial
to initiate sufficient T cell activation, and in the case of tumors,
an anti-tumor response (8). The process of T cell mediated tumor
elimination may also involve Fas mediated apoptosis, release of
cytotoxic molecules such as perforins, and indirect cellular killing
through release of interferon-gamma (7). There are limitations
in immune mediated control of tumors, such as tumor mediated
immune suppression (6). Therefore, immune strategies including
combination therapies with cytoreductive agents can be employed
to treat cancer have to help cytoreduce the tumor and overcome
some of these immune suppressive obstacles.
Prostate cancer is an excellent tumor target for immune-
based therapies. First and foremost, prostate cancer has an indo-
lent disease course, which allows the immune system to gener-
ate an immune response. In addition, prostate specific antigen
(PSA) allows for detection of disease when the cancer is at the
micro-metastatic level, allowing for small volumes of disease to
be treated. Given that increasing levels of tumor burden carry
increasingly immune suppressive attributes, starting immune-
based treatments with minimal tumor may be advantageous (9).
Also, prostate cancer has well characterized tumor associated anti-
gens (TAAs), which can serve as therapeutic immunologic tar-
gets (10–12). Together these characteristics may explain some of
the preliminary clinical success with immunotherapy in prostate
cancer, but more importantly they may be indications of true
therapeutic potential when optimized as part of combination
regimens.
IMMUNOTHERAPY IN PROSTATE CANCER
THERAPEUTIC CANCER VACCINES
The promise of immune-based therapies to control cancer has
come to fruition in recent years with the regulatory approval of
sipuleucel-T in prostate cancer and immune checkpoint inhibitors
in melanoma (13, 14). Therapeutic cancer vaccines such as
sipuleucel-T are designed to enhance immune recognition of spe-
cific TAAs, leading to immune-mediated killing of cancer cells.
Sipuleucel-T is a therapeutic cancer vaccine generated from a
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patient’s own immune cells, which are collected via apheresis, acti-
vated in ex vivo fashion, and then re-infused into the patient. The
ex vivo processing of immune cells is designed to enhance immune
recognition of the TAA prostatic acid phosphatase (PAP) (11). A
full course of therapy with sipuleucel-T consists of three infusions
every other week for 1 month. Early clinical trials demonstrated
the safety and tolerability of this treatment, which had minimal
side effects (15). Although two initial phase III trials in metasta-
tic castration-resistant prostate cancer (mCRPC) did not meet
their primary endpoint of improved time to progression, there
was a suggestion that they improved survival (15). In a third clin-
ical trial, sipuleucel-T extended the lives of patients with mCRPC
relative to placebo (25.8 vs. 21.7 months; HR= 0.78; p= 0.03)
leading to FDA approval in patients with minimally symptomatic
or asymptomatic mCRPC (13).
Another vaccine in late stages of clinical development is
PROSTVAC (PSA-TRICOM), a pox-viral vaccine developed to
stimulate the immune system via in vivo immunologic stimula-
tion at that is designed to enhance targeting of PSA (10). Unlike
Sipuleucel-T, PROSTVAC consists of recombinant pox viruses that
are injected into a patient subcutaneously and does not require ex
vivo processing of immune cells (16). Once within the patient, the
pox viruses infect including immune cells. Subsequently, recom-
binant genetic material within the virus is translated within the
cytoplasm of the DCs (10). This genetic material encodes for
PSA, the immunologic target, and 3 T cell co-stimulatory mol-
ecules that have demonstrated the ability to enhance T cell activity
in a synergistic manner (17). The end result is that the infected
DC serves as an APC, displaying PSA in an immunologic con-
text, along with co-stimulatory molecules, leading to TAA-specific
immune activation and targeted T cell destruction of tumor cells.
Early clinical trials demonstrated that common side effects were
limited to self-limiting injection site reactions and flu-like symp-
toms (18). Subsequent phase II studies demonstrated the ability
of this vaccine to improve T cell recognition of PSA (19). In addi-
tion a randomized, multi-center trial (n= 125) was conducted
in chemotherapy-naïve mCRPC patients with PROSTVAC vs.
placebo. The results were favorable, suggesting an improvement
in overall survival (25.1 vs. 16.6 months; HR= 0.56, p= 0.0061)
(20). Together these two studies have led to a randomized phase
III trial in chemotherapy-naïve mCRPC (NCT01322490).
IMMUNE CHECKPOINT INHIBITORS
Another immunotherapeutic approach involves the disruption of
immune regulation via monoclonal antibodies design to inhibit
immune checkpoints. Such therapies do not provide the immune
system with an immunologic target such as a TAA, but rather allow
amplified or sustained T cell activation in a non-specific fashion.
Although this can lead to a more aggressive response, it may lead
to immune related adverse events (irAEs) such as rash, colitis, and
endocrinopathies. Ipilimumab is the first-in-class agent designed
to bind to CTLA-4, a molecule expressed by T cells after activa-
tion. CTLA-4 binds CD80, a co-stimulatory molecule present on
APCs, and prevents CD80 from binding CD28, a co-stimulatory
molecule present on T cells. CTLA-4 is a competitive inhibitor of
the activating signal and results in T cell suppression or inacti-
vation (21). Ipilimumab binding to CTLA-4 prevents the natural
auto-regulatory interactions of T cells with APCs. This blockade
of CTLA-4 increases the likelihood of greater, albeit non-specific,
T cell activity (21). Such activity has potentially profound effects.
Indeed, CTLA-4 knock-out mice ultimately die from lymphocytic
infiltration of their organs (22).
Ipilimumab was FDA-approved for the treatment of metasta-
tic melanoma based on an overall survival benefit compared to a
peptide-based vaccine (GP100), which served as an active control,
although there was no change in short term disease progression.
Immune-related adverse events (irAEs) are the toxicities uniquely
seen with the use of checkpoint inhibitors. These events are
mechanism-based and chiefly include skin and mucosal rash (47–
68%), diarrhea/colitis (all grades, 44%), hepatotoxicity (3–9%),
and hypophysitis (1–6%) (14). Immunosuppressive agents such
as systemic steroids are the standard treatment for many irAEs,
which are thus reversible (23). For irAEs that impact endocrine
organs, replacement hormones may be required.
Ipilimumab has also been evaluated in prostate cancer. Pre-
liminary trials suggested activity as well as common irAEs seen
in studies in other tumor types (24–27). A recently completed
phase III trial evaluated ipilimumab combined with low dose
radiation as a potential immune enhancer (28). The placebo con-
trolled study was conducted in late stage mCRPC patients who
had already been treated with docetaxel. While the study was neg-
ative, there was a trend to improved survival (11.2 vs. 10 months
for placebo; HR= 0.85; p= 0.053), which was the primary end-
point of the study. A post hoc subgroup analysis suggested that
patients with indolent disease features who received ipilimumab
had a substantial improvement in survival compared to those
who received placebo. These data are encouraging because an on-
going study is evaluating ipilimumab in an earlier stage of disease,
chemotherapy-naïve mCRPC, has completed accrual and results
are pending (NCT01057810).
Agents blocking programed cell death protein-1 (PD-1) and
its ligand PD-ligand-1 (PD-L1) are other examples of immune
checkpoint molecules shown to have anti-tumor activity in solid
malignancies and appear to have an improved safety profile com-
pared to anti-CTLA-4 (29, 30). Lymphocyte activation gene 3
(LAG3) and B7-H3 are also novel targetable immune checkpoint
molecules currently in clinical development, while B7-H4 and T
cell membrane protein 3 (TIM3) inhibitors are in preclinical devel-
opment (31, 32). These treatments may also be investigated in the
future in prostate cancer.
BIOLOGICAL BASIS AND RATIONALE OF THE
COMBINATORIAL IMMUNOTHERAPY APPROACH
The opportunity to combine more standard, non-immunologic
therapies with immune-based therapies is derived from growing
understanding that these standard therapies may enhance immune
activity. Some cytotoxic therapies may induce an immunologic
form of cell death that serves to feed an on-going immune response
(33). Other therapies may kill cancer cells in a way that leads to
the release of “molecular danger” (34) signals that may improve
immune anti-tumor activity (35). Other therapies may impact the
tumor microenvironment in ways that enhance immune recog-
nition or killing of tumor cells (35, 36). These characteristics
have been extensively studied in the context of the standard
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FIGURE 1 | Interaction of immune cells with tumor cells. (a) Dendritic
cells present antigen via MHC class II to T cells via the T cell receptor (TCR).
Binding of co-stimulatory signaling molecules (signal 2) is required for
adequate T cell activation to occur. (b) Immune checkpoints are present at
several points of the immune response, which regulate T cell activity.
Blocking these interactions may enhance anti-tumor T cell activity. (c) In
response to activation via dendritic (or other antigen presenting) cell
signaling, T cells up-regulate specific TCRs and produce interferon-gamma
(IFN-γ), which induces tumor cells to express programed death receptor 1
ligand (PD-L1), perhaps making it a therapeutic target. (d) Tumor cell
destruction results in debris that is engulfed by APCs (including dendritic
cells), processed, and presented back to T cells. This process is the basis for
an immunotherapy-induced process known as antigen-cascade/antigen
spreading.
Table 1 | Effects on immune system of different interventions in
cancer.
Intervention Immunologic impact Example of
intervention
Hormone
manipulation
Increased thymic T cell production (38) LHRH antagonist
Potentiation of T cell response (39)
Decreased in Tregs [CD4+CD25+] (41)
Chemotherapy Increase antigen expression (77) Cyclophosphamide
Docetaxel
Oxaliplatin
APC activation (75)
Decrease in Tregs [CD4+CD25+] (71)
Induce ICD (75)
Radiation
therapy
DC activation (56) External beam
radiation
IMRT
Release of danger signal (HMGB1) (58)
Increase calreticulin expression (75)
Immune-
checkpoint
blockade
Increased aggressiveness immune
response (86)
Ipilimumab
Anti-PD-1
Anti-PD-L1Decreased Inhibitory signal of T
effector cells (84)
LHRH, luteinizing hormone-releasing hormone; IMRT, intensity-modulated radia-
tion therapy.
treatments used in prostate cancer and help provide a strong ratio-
nale for immunologic combinations to treat this disease (Figure 1;
Table 1).
ANTI-ANDROGEN THERAPY
Androgens fuel the proliferative mechanisms of prostate cancer
and thus anti-androgen therapy is the cornerstone of prostate
cancer therapy (37). A number of clinical and preclinical studies
have demonstrated the potential synergy between anti-androgen
therapy and immune stimulating therapies. These findings sup-
port combining immune-based treatments with several standard
therapies in prostate cancer.
Recent preclinical studies have confirmed the earlier findings
and shed light on the cellular changes that underlie the effect of
anti-androgens. Following surgical castration in aged mice, rever-
sal of thymic atrophy, restoration of thymic architecture, normal-
ization of thymocyte differentiation, proliferation, and levels of
apoptosis, are observed (38). Increased thymic import and restora-
tion of peripheral thymocyte pool and function have also been
noted. Similarly, LHRH treated older men, at 4 months showed
a significant increase in total peripheral lymphocytes (p≤ 0.05),
T cells (p≤ 0.01) (predominantly naive CD4+, as well as both
naive and memory CD8+ T cells), and natural killer (NK) cells
(p≤ 0.05) (39). In some patients, the changes are associated with
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a 25% increase in naïve T cells as measured by TCR excision circles,
a byproduct of new T cell production by the thymus.
Androgen ablation in mice mitigates tolerance of the tumor
to the immune system, suggesting that immunotherapy might be
more efficacious if used in combination with hormone ablation
(40). In mouse models of endogenous prostate cancer, accumula-
tion of functional T cells in the prostate glands is seen at about
2.5 weeks after castration. It is hypothesized that the antigens
released by dying prostate cancer cells may stimulate the CD8
T cells (41). A functionally effective, intra-prostatic population
of T cells can be augmented by in situ injection of vaccine in
PTEN-knock-out mouse models (42).
Recently, modern anti-androgens such as enzalutamide have
been developed and have demonstrated the ability to prolong
life in mCRPC with minimal side effects (43, 44). While these
advances have revolutionized the treatment landscape for prostate
cancer it has also created opportunities to explore synergy with
immunotherapy. Studies in murine models have demonstrated
that enzalutamide, like androgen deprivation therapy (ADT),
enhances the production of naïve T cells from the thymus
(45, 46). Clinical trials combining therapeutic cancer vaccines
and enzalutamide are currently underway (NCT01875250 and
NCT01867333).
In the human studies, ADT has demonstrated an immune
response in the form of a mononuclear cell infiltrate, a
response that peaks at 2–3 weeks (47). ADT modulates the sub-
type of immune cells that home on prostate as shown in a
computer-assisted analysis of prostatectomy specimens in 75
patients (ADT-treated, 35; control, 40) (48). Compared to the
controls, ADT-treated patients had a significant increase in rel-
ative density of CD3(+) (p< 0.001) and CD8(+) T-lymphocytes
(p< 0.001) as well as CD68(+) macrophages (p< 0.001). A prog-
nostic correlation was sought as well in the study. Elevated num-
bers of CD56(+) NK cells were found to be associated with a lower
risk of prostate cancer progression (p= 0.044), while a high den-
sity of CD68(+) macrophages was related to an increased risk of
biochemical recurrence (p= 0.011).
The safety and efficacy of autologous cellular cancer
immunotherapy (sipuleucel-T) has been studied in combination
with ADT in patients with non-metastatic castration-sensitive
prostate cancer (nmCSPC). A double-blind, controlled, multi-
center study randomized 176 patients with biochemical recurrence
(rising PSA) after prostatectomy into sipuleucel-T and placebo
arms. The treatments were instituted after a 3–4-month run-in
period of androgen suppression therapy (49). Compared to the
placebo arm, subjects who were given sipuleucel-T had a 48%
increase in PSA doubling time following testosterone recovery
(155 with sipuleucel-T vs. 105 days, p= 0.038). These data sug-
gest that sipuleucel-T can slow the growth of cancer over time and
this hypothesis is corroborated by additional data from clinical
studies with PROSTVAC (50).
At least two phase II randomized clinical trials are evaluating
the impact of sequencing ADT on systemic immune responses.
The first study (NCT01431391) is a phase II randomized trial
that will attempt to determine if ADT before or after vacci-
nation with sipuleucel-T leads to better immune responses in
nmCSPC patients. The results of this study could have implications
for future immunotherapy studies involving initiation of ADT.
The second study (NCT01487863), also a randomized phase II
investigation, will evaluate the use of concurrent or sequential
abiraterone and prednisone with sipuleucel-T in mCRPC. Pre-
liminary data suggested that abiraterone and prednisone when
given concurrently with sipuleucel-T did not diminish immune
stimulation seen with sipuleucel-T alone (51). These data are
important because they start to address a prevailing dogma, which
suggests that prednisone at 10 mg daily (an important part of sev-
eral mCRPC regimens) may diminish immune responses induced
by sipuleucel-T, although there are no clinical data to support these
concerns.
Combined androgen blockade involves the concomitant
administration of ADT and an androgen receptor antagonist
(ARA), such as nilutamide. One clinical trial combined androgen
blockade (CAB) with vaccines, using cross-over design (52). In
the trial, the patients who started on nilutamide first with vaccine
added only at PSA progression had a median time to treatment
failure of 5.2 months. In contrast, the median time to treatment
failure (defined by rising PSA or development of a metastatic
lesion) with the combined therapy was 13.9 months in the vac-
cine arm when nilutamide was added at PSA progression thus
favoring a strategy of early introduction of vaccine. A follow-up
analysis revealed a 75% 5-year survival rate for patients treated
first with vaccine in comparison to 43% 5-year survival rate for
patients who received nilutamide first and had vaccine added at a
later time (53). These data suggest that synergy of anti-androgen
therapy and immunotherapy may be optimized when the combi-
nations are deployed earlier in the disease course. As previously
discussed, newer ARAs such as enzalutamide have been developed
and combinatorial trials with these newer agents are on-going
(NCT01875250 and NCT01867333).
RADIATION THERAPY
Radiation therapy kills cells by inducing lethal DNA damage,
which in turn leads to apoptosis and cell death (54). Additional
effects include inflammation in the microenvironment, sub-lethal
injury to some of the tumor cells, changes in the tumor vas-
culature, and potentially activation of immune cells (55, 56).
Radiation can up-regulate TAAs, co-stimulatory molecules, Fas,
MHC moieties, cytokines, chemokines, and adhesion molecules,
and down-regulate regulatory T cells (Tregs), all of which ren-
ders tumors susceptible to immune attack. The release of TAA
and recruitment of APCs at the site of the debris, necrosis and
inflammation (increased expression of IL-1β and TNF-α) at the
site of radiation, can directly activate the immune system and cause
immune cell induced cytolysis (57). Specifically, the up-regulation
of immunomodulatory surface molecules such as MHC type I
and death receptors such as Fas have been demonstrated to medi-
ate specific immune mediated killing (58). Garnett et al. showed
that sub-lethal doses of radiation change the phenotype of the
human tumor cell lines increasing, mucin-1, CEA, and MHC class
I. These changes augment the killing of the tumor cell by specific
CD8(+) T cells restricted or specific to this phenotype (59).
The combinatorial efficacy of radiation and adoptive cell trans-
fer of cytotoxic T cells in a preclinical model was demonstrated by
Chakraborty et al. (60). Sub-lethal doses of irradiation in a mouse
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adenocarcinoma model increased the anti-tumor activity of ACT
Ag-specific cytotoxic T cells by utilizing the Fas/Fas ligand path-
way of tumor death. Radiation and immunotherapy using Listeria
monocytogenes-based vaccine (ADXS31-142) was investigated in
a mouse model of prostate cancer. Together, they demonstrated a
greater delay in tumor growth, increase in specific cytotoxic T cells
and high level of interferon production compared to the animals
that did not receive the combined treatment (61).
Gulley et al. tested the combination of definitive external beam
radiation therapy plus vaccination in localized prostate cancer
patients (62). In this randomized phase II trial patients received
radiation alone or radiation combined with a viral vaccine con-
struction (PSA gene inserted and B7.1 co-stimulatory gene). The
results showed an increased PSA-specific T cell response in the
combination compared with the radiation alone arm (p< 0.0005).
In addition to the demonstration of immunologic responses, the
combination was safe without major toxicity; the only grade 3
events were attributed to the IL-2 given as adjuvant to the vaccine.
A similar experience by Lechleider et al., using a lower dose of
IL-2 during several days (metronomic) with radiation therapy in
patients with localized prostate cancer showed significant increases
in PSA-specific-T cell responses and lower toxicities (63).
In addition to external beam radiation, therapeutic radiation
can also be delivered via radiopharmaceuticals. Agents such as
samarium-153 EDTMP are designed to localize to remodeled
bone, which are likely sites of metastatic cancer. Once there, the
radiation component (samarium-153) emits radioactive particles
that can kill cancer cells via DNA damage. This agent is approved
for palliation in patients with mCRPC (64). Like external beam
radiation, radiopharmaceuticals have been shown to also alter the
phenotype of cancer cells and enhance killing by immune cells
(65). A clinical trial has combined PROSTVAC with samarium-153
in patients with mCRPC who had progressive disease on stan-
dard front-line chemotherapy, docetaxel. Preliminary data suggest
that samarium-153 combined with vaccine prolonged progres-
sion free survival (PFS) more than samarium-153 alone (3.7 vs.
1.7 months; HR= 0.48, p= 0.034) (66). These data are especially
interesting given recent the innovation of radium-223, which
has similar properties as samarium-153, but a more reasonable
side effect profile. Furthermore, this agent has demonstrated an
ability to improve survival in mCRPC, raising the intriguing pos-
sibility of future combination studies involving radium-223 and
immunotherapy (67).
A completed phase III trial in mCRPC has already used radi-
ation as a form of immune adjuvant to potentially enhance the
clinical impact of immunotherapy (28). This trial was also con-
ducted in men with mCRPC who had previously progressed on
front-line chemotherapy. Patients were randomized to external
beam radiation to isolated bone lesions with either ipilimumab or
placebo. The role of radiation was not palliative, but the 8 gy dose
was designed to alter the cancer cells within the lesions, as previ-
ously discussed, with the goal of potentiating an immune response
(68). The trial did not meet its primary endpoint, despite a trend
toward an overall survival benefit in patients treated with radiation
and ipilimumab compared to radiation and placebo (11.2 months
vs. 10 months; p= 0.053, HR= 0.85) (28). There was also a trend
to improved survival seen in patients with more indolent disease
features suggesting that future studies may be optimized by focus-
ing on similar populations. Although the results fell short of
expectations, this study provides hypothesis-generating data for
future studies and evidence that using radiation as an immune
adjuvant is feasible in large randomized trials.
CHEMOTHERAPY
Cytotoxic chemotherapies have been traditionally considered to
be immunosuppressive, but emerging data are now starting to
dispel that dogma as well. Many chemotherapeutics agents like
cyclophosphamide and methotrexate cause leukopenia and lym-
phopenia and have been used for many years as immunosuppres-
sive agents (69). Others such as the nucleoside analogous cladrib-
ine and fludarabine cause more profound T cell depletion (70). In
addition to the known effects on the immune system, accumulat-
ing evidence demonstrates that cytotoxic drugs may augment the
anti-cancer immune response and potentially be synergistic with
immunotherapy approaches (33).
Notably, with cytotoxic therapy, the decrease in the host’s lym-
phocyte population can be selective, as has been shown in case
of cyclophosphamide. Specifically, the drug diminishes the T cell
subpopulation that is CD4+CD25+ FOXP3+ T cells, also known
as Tregs (71). Tregs suppress the activation of the immune sys-
tem and prevent pathological self-reactivity; a good example of
this paradigm is in the prevention of autoimmune diseases. Initial
observation as to the selective cytotoxicity of cyclophosphamide
on Tregs was described in a seminal paper published by North
et al. (72). Using a mouse model, these data demonstrated that the
combination of adoptive cell transfer of T cells in the presence of
cyclophosphamide was better in achieving tumor regression com-
pared to the control. Several strategies in modern immunotherapy
against cancer involve some type of decrease in the number and
function of Tregs with cyclophosphamide (73, 74).
Another key concept in the combination of immunotherapy
and chemotherapy is immunogenic cell death (ICD), which refers
to the capacity of tumors cell to elicit an immune stimulatory
response after death or lethal injured induce by cytotoxic ther-
apies. Based on several hypothesizes, critical steps in ICD may
involve exposure of calreticulin at the surface of dying tumors
cells, HMGB1 secretion, and ATP release, all of which increase
the uptake of tumor antigens by the surrounding DCs and initi-
ate an immune response (75, 76). The in situ immunogenic effects
observed with agents such as oxaliplatin, mitoxantrone, cyclophos-
phamide, and doxorubicin as well as certain types of radiation on
the susceptible host cells have been explained via the induction of
ICD (75, 76).
Cytotoxic drugs may also augment anti-tumor immune
response via the phenomenon of immunogenic modulation. As
opposed to lethality-associated ICD, immunogenic modulation
results from the sub-lethal effects of chemotherapy on the tumor
that brings about a change in the surface antigen expression (phe-
notypic change). Docetaxel,which is one of the two cytotoxic drugs
approved in metastatic prostate cancer, has been demonstrated to
replicate this process in low doses in preclinical models through
up-regulation of cell surface molecules like ICAM-1, MUC-1, and
MHC class 1 molecules (77). Hodge et al. demonstrated the effects
of docetaxel administration in non-lethal doses in a variety of
www.frontiersin.org December 2014 | Volume 4 | Article 351 | 5
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Burotto et al. Immune base combinations prostate cancer
cell lines and xenograft models. Tumor cells did not necessar-
ily die by ICD, but rather there was an increased sensitivity to
antigen-specific cytotoxic T cell killing and a broadening of the
immune response resulting in the targeting of multiple antigens
(antigen-cascade/spreading discussed later) (78).
Clinical experience in prostate cancer utilizing the combina-
tion of chemotherapy and vaccines has been reported by Arlen
et al. The phase II trial randomized 28 patients to docetaxel plus
viral-vector based vaccine (vaccinia and fowlpox virus expressing
PSA gene and the co-stimulatory gene B7.1) vs. vaccine alone. The
combination was deemed safe; immune responses, as measured by
antigen-specific-T cell activation against PSA antigen were equiv-
alent in both arms with a median PFS in the docetaxel arm of
6.1 months, which was favorable when compared with a historic
control (3.7 months) (79). Interesting data from a study involving
breast cancer may have particular relevance in prostate cancer due
to the use of docetaxel chemotherapy in combination with PAN-
VAC, a pox-viral vaccine, targeting MUC-1 and CEA and encoding
three co-stimulatory molecules, similar to PROSTVAC, and sug-
gest the benefit of the combination in metastatic breast cancer
(PFS of 6.6 vs. 3.8 months, HR= 0.67) (80, 81).
The potential for immunotherapy combinations with
chemotherapy in prostate cancer may have more poten-
tial in light of recent data that suggest docetaxel in
newly metastatic castration-sensitive disease (with high volume
tumor) have substantially delayed disease progression (49.2 vs.
32.2 months; HR= 0.60) (82). Given that some data suggest that
immunotherapy may have its optimal impact early in the dis-
ease process, there may be natural opportunities for combination
studies in this disease setting in the future (53, 83).
COMBINING IMMUNOTHERAPIES: VACCINES PLUS
CHECKPOINT BLOCKADE
The rationale for the combination of vaccines and checkpoint
inhibition is based on the complimentary mechanisms of these
therapies. Vaccines are intended to activate immune cells and ipil-
imumab is designed to increase T cell activation and killing by
blocking immune auto-regulatory mechanism through CTLA-4
blockade (84). Preclinical evidence attests to the ability of anti-
CTLA-4 antibodies in improving cytotoxic T-lymphocytes (CTLs)
avidity as well. Since high avidity CTLs may have more pronounced
anti-tumor efficacy, it provides additional justification to com-
bine ipilimumab and vaccines in clinics as a therapeutic maneuver
against prostate cancer (85–87).
The rationale of combining therapeutic cancer vaccines with
ipilimumab (to augment T cell avidity) was tested in a Phase I study
that combined GVAX with escalating doses of ipilimumab (0.3–
5 mg/kg) in patients with mCRPC (27). Seven of 28 patients (25%)
who received either 3 or 5 mg/kg ipilimumab had PSA declines of
≥50% while 2 patients showed a clear regression of bone metas-
tases. irAEs were similar in incidence and character as had been
previously observed with single agent ipilimumab.
In a second trial involving patients with mCRPC, PROST-
VAC was evaluated in combination with ipilimumab in escalating
doses of 1–10 mg/kg (25). No dose-limiting toxicities were seen
and again side effects typical of ipilimumab were observed. Four-
teen (58%) of 24 chemotherapy-naive patients had PSA declines
out of which 6 (25%) had declines >50% and 2 of these 6 had
declines >90%. In addition, the median survival in these patients
with mCRPC was >34 months, which compares favorably to sin-
gle agent immunotherapy trials in the same population (19, 20,
25).
Together, these trials suggest that, when used in combination,
therapeutic cancer vaccines do not enhance the toxicity of anti-
CTLA-4 antibodies. Preliminary evidence of efficacy for this com-
bination strategy of immune-checkpoint inhibition and vaccine
needs to be confirmed in large randomized studies. In addition,
anti-PD-1 and anti-PD-L1 are also in clinical development, with
the first agent having been just approved by the FDA in melanoma
(29, 30, 88). Given that these agents have demonstrated less toxic-
ity, future combinations with vaccines and anti-PD(L)1 are likely
to be clinically evaluated (29, 30, 88).
ANTIGEN-CASCADE/SPREADING
Perhaps the least appreciated aspect of immunotherapy is its
potential to increase its therapeutic breadth over time, which is a
significant distinction from other therapeutics. This can be accom-
plished by additional antigens being incorporated into an immune
response as cancer cells are killed by immune cells or other forms of
cytotoxic therapy. As the active immune response encounters new
antigens in the tumor microenvironment, they could be included
as new immunologic targets for the next generation of immune
cells (89). In this manner, immune-based therapies can be more
dynamic than cytotoxic therapies, which often have a limited range
of therapeutic targets that can ultimately be circumnavigated by
the intrinsic heterogeneity likely present within all tumors (90,
91). Although antigen-cascade has been seen in several trials, in
multiple cancers, and associations have been made with positive
outcomes, additional prospective data are required to determine its
potential role as a biomarker or intermediate marker of response
(62, 92–94). At this point, observations of antigen-cascade pro-
vide proof of concept of how immunotherapy can be used to
induce a biologically diverse anti-tumor effect. Future trials, per-
haps involving combinations, will look to build on this immune
response.
CONCLUSION
Immunotherapy in prostate cancer has emerged as a viable ther-
apeutic option and with multiple agents in the late stages of
clinical development it is possible the immunotherapeutic portfo-
lio for this disease could expand in the near future. The potential
to develop immune-based synergistic combinations in prostate
cancer could further optimize the clinical development of these
immune enhancing therapies. At each stage of prostate cancer
there is sound preclinical rationale for developing such combi-
nations, including newly diagnosed patients (radiation), nmC-
SPC (ADT), and mCRPC (anti-androgen therapy and docetaxel)
(Table 2). The future role of immunotherapy may be in improving
the efficacy of these standard therapies. But perhaps the great-
est potential for these combinations will be their use in patients
with localized disease to perhaps increase the cure rate of the
disease or induce functional cures allowing men to live longer
lives with prostate cancer. In the best case scenario, immune
stimulating therapies can help turn immune cells into sentinels
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Table 2 | Clinical trials using immune combinations in prostate cancer.
Author Study type population
(Number of patients)
Interventions Outcomes and comments
RADIATION COMBINEDWITH IMMUNOTHERAPY
Gulley (62) Phase II RCT localized disease
suitable for radiation [30]
Definitive EBRT± vaccine Threefold increase in PSA T cells vs. no detectable increase in
EBRT arm (p<0.0005)
Lechleider (63) Phase II localized disease
suitable for radiation [30]
Definitive EBRT vaccine IL-2
(metronomic low dose)
Safe administration and induction of PSA-specific T cells
Demonstration of reactive T cells against XAGE-1 and PAGE-4
Heery (66) Phase II RCT mCRPC (bone
disease) [68]
Sm-153± vaccine Increased PFS with Sm-153+ vaccine compared to Sm-153
alone
Kwon (28) Phase III RCT in mCRPC after
docetaxel [799]
Low dose radiation± ipilimumab Negative phase III trial, however a trend to OS (HR 0.85
p=0.053)
Benefit in subpopulation of patients with favorable prognosis
ANDROGEN DEPRIVATIONTHERAPY COMBINEDWITH IMMUNOTHERAPY
Mercader (47) Phase II T1–2b without
previous treatment [35]
ADT prior to RP Increase T cell and mononuclear cell infiltrates plus tumor
atrophy and involution
Madan (53) Phase II RCT nmCRPC [42] Vaccine vs. nilutamide
(with cross-over)
Improved survival in patients receiving vaccine earlier in the
disease course
Beer (49) Phase II RCT CSPC with PSA
recurrence only [176]
ADT± sipuleucel Data suggest that vaccine slows the growth rate of tumors
(prolonged PSA doubling time)
Small (51) Phase II RCT
asymptomatic/minimally
symptomatic mCRPC [63]
Sipuleucel T+AAP (concurrent)
Sipuleucel T→AAP (sequencial)
Preliminary data suggest that 5 mg prednisone BID did not
diminish APC activation or CD54 up-regulation
CHEMOTHERAPY COMBINEDWITH IMMUNOTHERAPY
Arlen (79) Phase II mCRPC in
progression [28]
Docetaxel+ vaccine vs. vaccine No decrease in generation of antigen-specific T cells when
docetaxel was added to vaccine
RCT, randomized clinical trial; EBRT, external beam radiation therapy; mCRPC, castration-resistant prostate cancer; PFS, progression free survival; OS, overall survival;
Sm-153, samarium-153; HR, hazard ratio; ADT, androgen deprivation therapy; RP, radical prostatectomy; CSPC, castration-sensitive prostate cancer.
who guard against the cancer inducing morbidity and mortal-
ity. Future randomized trials with immune-based combinations
will help determine if such regimens can truly revolutionize how
prostate cancer is treated and perhaps more importantly,how often
localized disease can be cured.
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